Women are 30% more likely than men to develop arthritis, and the divergence begins around age 50 — driven by estrogen decline that accelerates cartilage loss, triggers systemic inflammation, and doubles the rate of bone density loss to 2% per year at menopause.
2
Running does NOT cause arthritis — runners are actually less likely to develop arthritis than age- and sex-matched non-runners; arthritis is primarily an inflammatory and biochemical process, not a mechanical wear-and-tear one, and motion is essential for cartilage nutrition.
3
Menopausal hormone therapy initiated within 10 years of menopause reduces hip fracture risk by 30%, vertebral fracture risk by 40%, and all-cause mortality by roughly 30% — yet most women are not offered it until age 65, by which point the 10-year initiation window has closed.
4
Two types of collagen supplement address different joint needs: undenatured type-2 collagen (UC-2, 40 mg capsule) works via GI oral tolerance to reduce cartilage breakdown enzymes, while hydrolyzed type-2 collagen (500 mg powder) reduces symptoms of early knee arthritis; hydrolyzed type-1 collagen has randomized trial evidence for improving bone density in menopausal women with low bone mass.
Protocols
Concrete recipes — what, when, how much, and why
7 items
Strength training + impact loading (50+ jumps/session) + balance training for adult bone density
WhatMulti-component program combining higher-intensity compound resistance lifts (overhead press, squat, deadlift, upper- and lower-extremity loaded movements) with deliberate impact loading (jump rope, jumping jacks, box jumps, or even 30 jumps holding a chair back) and balance work, a few sessions per week.
WhenFrom age 30 onward, lifelong. Critical priority for women entering perimenopause or post-menopause. Start at whatever intensity is safe given individual arthritis and balance status.
Dose50+ jumps per session, a few days per week, combined with strength training. Studies showing measurable bone density gains run 6–8 months at 2–3 sessions/week. Gains average a few percentage points — small in absolute terms but meaningful when natural loss is 1–2%/year.
For whomAdults concerned about osteoporosis or bone maintenance. Modify for knee arthritis — pool jumping, chair-supported jumps, or lower-intensity work still yields benefit.
WhyImpact creates roughly 2x ground reaction force versus walking, providing peak strain rate stimulus for osteocyte signaling and new bone formation. Strength training provides the muscle-tension-on-bone signal. Pool-based jumping is an alternative for those with significant knee arthritis.
CaveatsHigher-intensity strength training yields more bone density benefit than moderate-intensity, but any loading is better than none. Fall risk must be assessed before unsupervised plyometric work in older adults.
Dr. Wittstein reviews the research literature: programs combining strength + impact training show bone density gains of a few percentage points over 6–8 months — comparable in magnitude to bisphosphonate drug treatment (~6% over 2 years), but the bone laid down through loading is better organized and deposited in the correct stress-bearing areas. Bisphosphonates prevent resorption without stimulating formation in load-specific patterns, and long-term use is associated with atypical subtrochanteric fractures as bone remodeling is suppressed too uniformly. Impact exercise also improves balance and fall prevention — addressing both sides of the fracture-risk equation simultaneously.
Mechanism
Axial loading and impact generate mechanical strain on bone that triggers osteocyte signaling, suppressing sclerostin and shifting the resorption/formation balance toward formation. The landing phase of a jump produces peak strain rates that steady-state loadbearing cannot replicate.
The most effective programs seem to combine some impact and some strength training. It doesn't have to be a ton of impact training — one of the studies showed improvement in bone density using like 50 jumps per session a few days a week added to the strength program and it made a difference.
Supplement stack for bone health: calcium + vitamin D 2,000 IU + vitamin K2 + magnesium glycinate 400 mg
WhatDaily: calcium (preferably from food; supplement if diet is poor), vitamin D 2,000 IU, vitamin K 100 mcg (often co-formulated with vitamin D), and magnesium glycinate 400 mg at night.
WhenDaily, ongoing — especially for perimenopausal and postmenopausal women and anyone with documented low bone density.
DoseVitamin D: 2,000 IU/day (studied for joint pain reduction in arthritis AND bone support). Magnesium glycinate: 400 mg at night (aids sleep, activates vitamin D). Vitamin K: 100 mcg/day (directs calcium to bone matrix).
For whomAnyone with inadequate dietary intake of these micronutrients, all women entering menopause, and anyone with osteopenia or osteoporosis. Magnesium glycinate preferred for tolerability.
WhyThe micronutrient chain: magnesium activates vitamin D → vitamin D enables calcium absorption → vitamin K2 directs calcium into bone rather than soft tissue. All four work synergistically.
CaveatsVitamin D at 2,000 IU/day is above the standard daily value — discuss with a physician if on medications affecting vitamin D metabolism. Calcium supplements carry theoretical cardiovascular risk compared to dietary calcium; dietary calcium first where possible.
Dr. Wittstein walks through the chain in clinic: 'Magnesium helps activate vitamin D, which then helps with calcium absorption. And then vitamin K in simple terms helps guide calcium to the bone for incorporation.' She personally takes magnesium glycinate 400 mg at night. Vitamin D at 2,000 IU has randomized evidence for reducing joint pain in arthritis patients, possibly because it improves subchondral bone quality adjacent to cartilage. The supplement stack does not replace MHT for postmenopausal bone loss prevention — it is a necessary but insufficient layer.
Vitamin D — for people who have knee pain I like them to take 2,000 units per day. That dose has been studied to reduce joint pain in people with arthritis. Calcium we'd rather you get through food. Magnesium glycinate 400 milligrams at night can help with sleep and certainly can help with your bone health.
Collagen protocol: UC-2 40 mg + hydrolyzed type-2 500 mg for joint symptoms; hydrolyzed type-1 500 mg for bone
WhatFor joint symptoms (early arthritis, cartilage protection): UC-2 undenatured type-2 collagen 40 mg capsule daily + hydrolyzed type-2 collagen 500 mg powder mixed into liquid. For bone density support: hydrolyzed type-1 collagen 500 mg daily (look for Fortibone formulation which has RCT evidence).
WhenDaily, ongoing. Can be combined with the vitamin D/K2/magnesium/calcium stack.
DoseUC-2: 40 mg capsule daily. Hydrolyzed type-2: 500 mg powder daily for joint symptoms. Hydrolyzed type-1: 500 mg powder daily for bone density.
For whomWomen with early knee arthritis or cartilage wear (UC-2 + hydrolyzed type-2); perimenopausal and postmenopausal women with low bone density (hydrolyzed type-1). Dr. Wittstein recommends trying both UC-2 and hydrolyzed type-2 together for joints.
WhyUC-2 works via GI oral tolerance — suppresses immune enzymes that break down cartilage; RCTs show lower cartilage breakdown products. Hydrolyzed type-2 collagen reduces pain in early knee arthritis. Hydrolyzed type-1 collagen is the main collagen type in bone; Fortibone RCT showed bone density gains in menopausal women comparable to exercise programs.
CaveatsHydrolyzed collagen for skin/hair/nails (type-1 and type-3) and for joints (type-2) are often sold interchangeably — verify type on label. Collagen protein quality score is low — do not rely on it as a protein source. The Fortibone bone density data are specific to that brand.
Dr. Wittstein changed her clinical recommendation after deep literature review. The two types work differently: UC-2 may slow progression (less breakdown products), while hydrolyzed type-2 addresses symptoms without changing progression. For bone: the Fortibone data 'found improvement in bone density in menopausal women with low bone density. And then they did a small subset several years later and showed an actual continued increase — that is fascinating.' Gains in the same range as exercise-based programs.
There is evidence regarding collagen supplements for joint health. A patient would ask me about collagen, I would say, 'That's dumb. Don't do that.' And then I went down a lot of rabbit holes and the more I read, I actually now recommend it to people.
Menopausal hormone therapy (transdermal preferred) within 10 years of menopause
WhatInitiate transdermal estrogen (patch) within 10 years of menopause onset for prevention of osteoporosis, reduction of joint pain, and reduction of frozen shoulder risk. Add progesterone coverage if the uterus is intact. Testosterone for bone and muscle is not yet FDA-approved for women outside of low libido.
WhenWithin the first 10 years after menopause. Women with risk factors should get a baseline DEXA at 40 and discuss MHT initiation earlier in perimenopause.
DoseModerate dose transdermal estrogen initially; dose typically increases after full menopause. Ongoing — the protective effect on bone density and joint pain reverses when therapy is stopped.
For whomPerimenopausal and early-postmenopausal women, especially those with any osteoporosis risk factor, joint pain, or frozen shoulder. Requires evaluation with a women's-health specialist. Progesterone required if uterus is intact.
WhyMHT reduces hip fracture risk 30%, vertebral fracture risk 40%, and all-cause mortality approximately 30%. Transdermal route bypasses hepatic first-pass, eliminating the clotting risk seen with oral estrogen.
CaveatsOff-label for joint pain and frozen shoulder prevention. Transdermal estrogen at MHT doses has no increased clotting risk in non-injured population; oral estrogen and combined oral contraceptives do carry clotting risk. Depo-Provera reduces bone density and should be avoided.
Mechanism
Estrogen drives apoptosis of osteoclasts (bone-resorbing cells), preventing excess bone loss. In synovium, estrogen receptors suppress fibroblast activation and inflammatory cytokines IL-1, IL-6, TNF-alpha, preventing capsular scarring and slowing cartilage degradation.
Transdermal estrogen used at the level in menopausal hormone therapy has no increased risk of clotting as opposed to the oral versions which do. And that's because the transdermal delivery basically bypasses that first pass through the liver that can affect the clotting cascades.
Also said
“Menopausal hormone therapy could be considered a life-saving thing. It reduces your risk of a hip fracture by 30%, reduces your risk of a vertebral fracture by about 40%, and reduces your all-cause mortality by about 30%.”— The magnitude of benefit that justifies the 10-year window urgency message.
Early frozen shoulder: glenohumeral joint steroid injection within 3 months of symptoms
WhatAt the first sign of adhesive capsulitis — pain at end range of external rotation at the side, difficulty reaching across the body, no history of trauma — seek a glenohumeral joint steroid injection before the joint becomes purely stiff.
WhenWithin the first 3 months of symptoms, while still in the painful-and-not-yet-stiff or painful-and-stiffening phase. Do not wait until purely stiff — at that point the joint typically thaws over about 1 year.
DoseSingle glenohumeral joint steroid injection; occasionally a second injection is required. 'If you inject their shoulder, usually within 3 months of symptoms, the things reverse really nicely.'
For whomWomen aged 40–60 (primary population). Also any woman with shoulder pain + night sweats + sleep disruption + mood changes — refer in parallel to women's health for MHT evaluation.
WhyFrozen shoulder is an inflammatory fibroblast-driven thickening and scarring of the joint capsule. Early steroid injection suppresses the inflammatory cascade before scar tissue matures. This is 'the best indication for a steroid injection in all of orthopedics.'
CaveatsOnly effective in the painful (pre-frozen) stages. Women with frozen shoulder and vasomotor menopause symptoms should be simultaneously evaluated for transdermal estrogen.
Dr. Wittstein describes her own experience: self-diagnosed adhesive capsulitis weeks before recording, immediately called colleague Dr. Anne Ford, got the glenohumeral injection, and started transdermal estrogen. Early signs: pain at end range of external rotation (arm at side, rotating outward), difficulty reaching across to the opposite armpit, fastening a bra, or tucking in a shirt. Some patients report vague hand tingling — probably mild brachial plexus irritation from capsular inflammation spilling to adjacent nerves. Full resolution including tingling within 3 months if caught early.
If you inject their shoulder, usually within 3 months of symptoms, the things reverse really nicely. Usually their range of motion goes back and occasionally you have to inject them one other time, but it is a full resolution.
Curcumin 1,500 mg/day with piperine to reduce joint pain and NSAID dependence
WhatDaily curcumin supplementation at 1,500 mg, formulated with piperine (black pepper extract) to enhance bioavailability.
WhenDaily, ongoing, for anyone with early osteoarthritis, joint pain, or seeking to reduce NSAID use.
Dose1,500 mg curcumin per day combined with piperine. This is the studied dose showing clinical benefit.
For whomAdults with early osteoarthritis or joint pain, those seeking to reduce NSAID use, perimenopausal/postmenopausal women with joint inflammation.
WhyCurcumin modulates the same inflammatory cytokine pathways (IL-1, IL-6, TNF-alpha) that drive cartilage breakdown in osteoarthritis. RCTs at this dose showed reduced need for anti-inflammatories and reduced joint pain in early arthritis patients.
CaveatsCurcumin has poor bioavailability without piperine — ensure the formulation includes it. Not a substitute for physical therapy or structural interventions if arthritis is advanced. Not a bone-density intervention.
Dr. Wittstein places curcumin alongside vitamin D as her primary non-pharmaceutical anti-inflammatory recommendation for joint health. In context with omega-3 fatty acids, curcumin represents a safer long-term inflammation management strategy than daily ibuprofen or naproxen: 'There's actual real evidence behind that.' Both target the inflammatory cytokine environment that contributes to cartilage degradation, without the GI/renal/cardiovascular costs of chronic NSAID use.
1,500 milligrams per day of curcumin has been studied shown to reduce need for anti-inflammatories, reduce joint pain in people with early arthritis. And it's usually combined with piperine. There's actual like real evidence behind that.
DEXA baseline scan starting at age 40 with any risk factor — not waiting until age 65
WhatGet a DEXA scan at age 40 if any risk factor is present: approaching or in perimenopause, Caucasian ethnicity, thin or underweight, family history of osteoporosis, personal history of amenorrhea or relative energy deficiency syndrome. Under age 50, interpret by Z-score not T-score.
WhenAge 40 with any risk factor. No later than shortly after menopause onset. Do not wait for the standard guideline age of 65.
DoseSingle DEXA scan for baseline; repeat at intervals guided by results. T-score −1.0 to −2.5 = osteopenia; below −2.5 = osteoporosis. Under 50 use Z-score.
For whomAll women with any of the named risk factors. Even women without risk factors benefit from a baseline before menopause so they have a comparison point.
WhyThe standard recommendation (first DEXA at 65) puts women outside the 10-year MHT initiation window if they entered menopause at 52. A baseline at 40–50 allows early identification of osteopenia when pharmacological and lifestyle interventions including MHT are still most effective.
CaveatsDEXA measures bone mineral density, not bone quality or architecture. Site-specific: lower extremity impact loading specifically increases femoral neck and cortical density.
A lot of people are missing the boat. There are a lot of people who are seeing doctors who got their medical training when there was a lot of misinformation about menopausal hormone therapy and don't provide it — and it truly is indicated for prevention of osteoporosis.
What's new
Personal practice updates, fresh positions, predictions
7 items
Estrogen is the master regulator of musculoskeletal aging in women
~8 min
Estrogen receptors are present in skeletal muscle, bone, joint synovium, tendons, and ligaments. When estrogen declines at menopause, inflammation rises, cartilage degrades faster, osteoclasts survive longer (driving bone loss), and muscle becomes harder to maintain. Women hit a steep decline around age 50 that men don't reach until their 80s.
Why this matters: Frames what mainstream medicine still calls separate problems — frozen shoulder, arthritis, osteoporosis, tendinitis, muscle loss — as expressions of a single hormonal transition, opening a unified prevention window.
Background
Before this framing, frozen shoulder was labeled idiopathic, menopausal joint pain was dismissed as vague complaint, and osteoporosis was treated as a stand-alone disease detected at 65 — too late to act on the prevention window.
Dr. Wittstein explains that estrogen drives apoptosis of osteoclasts (the bone-resorbing cells). Without estrogen, osteoclasts survive longer and break down more bone — explaining the jump from 1% to 2% bone loss per year at menopause. In joints, the same estrogen deficit elevates inflammatory cytokines IL-1, IL-6, and TNF-alpha within the synovium, accelerating cartilage breakdown. Women are not only 30% more likely to develop arthritis but present further into the disease — meaning the real sex difference is probably underestimated. Estrogen decline also explains the spike in tendinitis and periarticular pain that women experience during perimenopause, a period during which standard sports-medicine protocols designed for men often fail.
Estrogen is a major anti-inflammatory hormone and there are estrogen receptors all over the human body — skeletal muscle, bones, synovium of joints, your tendons and ligaments. When we get estrogen decline we get higher levels of inflammation.
Also said
“Women hit this age around 50 where there's a big increase in rates of and progression of arthritis, more bone loss, more progression towards osteoporosis. Men don't see that dramatic decline. And things don't really even out for men and women until we're like 80 years old.”— Quantifies the timeline of sex-based divergence — not a subtle difference, a 30-year gap.
Running does NOT cause arthritis — runners have LESS arthritis than non-runners
~55 min
Studies comparing runners to age- and sex-matched non-runners consistently show runners are less likely to develop arthritis. MRI studies show cartilage compresses only ~3% during running and fully rebounds by the next day. Cartilage is avascular and gets nutrients through joint fluid — motion is how it feeds itself.
Why this matters: Directly contradicts a pervasive clinical and lay belief that discourages the very activity that best protects joints. The 'wear and tear' model of arthritis is mechanistically wrong for most people.
Background
The wear-and-tear framing arose from arthritis being labeled 'osteoarthritis' — but even osteoarthritis has elevated IL-1, IL-6, and TNF-alpha within the joint, making it a mixed biomechanical-inflammatory condition, not simple mechanical erosion.
Dr. Wittstein describes a study where subjects ran and then had their knees MRI-imaged: cartilage compressed by about 3% but returned to full thickness by the next day. 'Cartilage is like a little sponge — it gets nutrients through the joint fluid. So motion is good for joints.' The important caveat: if someone already has unrecognized arthritis, running may make it symptomatic (swelling, pain) even though it did not cause it. For obese patients, loading per step is proportionally higher and cartilage quality is already compromised, so Dr. Wittstein recommends building muscle and doing lower-impact cardio first before transitioning to running.
If you look at studies that compare runners to non-runners, runners are less likely to have arthritis than age and sex matched groups.
Also said
“Motion is lotion. Joints do not like to be immobilized. That's kind of how cartilage receives nutrition and hydration — is through movement.”— The physiologic principle behind the counterintuitive finding: movement is the mechanism by which cartilage is nourished.
Frozen shoulder is almost certainly an estrogen-mediated condition
~28 min
Adhesive capsulitis occurs overwhelmingly in women aged 40–60 and — in men — almost exclusively in poorly-controlled diabetics (another high-inflammation state). Animal studies show estrogen receptors in shoulder synovium; applying estrogen reduces inflammation and fibrosis. A 2023 single-center paper found HRT associated with reduced risk of adhesive capsulitis in menopausal women.
Why this matters: Reframes a 'mystery diagnosis' as a downstream symptom of the menopausal transition — and makes early intervention with HRT a plausible upstream prevention, not just intra-articular steroid as the downstream patch.
Background
Frozen shoulder was labeled 'idiopathic' for decades. The fibroblast activation that causes capsular scarring is now understood to be triggered by estrogen deficiency, based on animal and mechanistic data.
Dr. Wittstein, a 47-year-old orthopedic surgeon, self-diagnosed adhesive capsulitis a few weeks before the recording. Her response: (1) immediately get a glenohumeral joint steroid injection — 'the best indication for a steroid injection in all of orthopedics'; (2) start transdermal estrogen. The clinical course is predictable: painful and not stiff → painful and stiff → just stiff. If caught in the first two stages, a single glenohumeral steroid injection typically achieves full resolution within 3 months. If the patient waits until the purely-stiff stage, it thaws over about a year with no shortcut. Dr. Wittstein now collaborates closely with Dr. Anne Ford at Duke Women's Health — when patients present with a frozen shoulder AND night sweats/depression/sleep disruption, she sends them to women's health in parallel.
It was labeled as idiopathic forever. And you know what idiopathic means? It means we just don't know what causes it. But how can it be idiopathic if this happens mostly in women and not in men?
Also said
“There are these estrogen receptors in the synovium of the shoulder and applying estrogen to the tissue of the lining of the shoulder can reduce levels of inflammation and reduce the fibrosis.”— The mechanism that makes frozen shoulder a hormone-responsive condition with a modifiable upstream lever.
“77% of menopausal women in their study had joint pain and when treated with menopausal hormone therapy with estrogen there was significant decrease in joint pain, number of joints that were painful, and severity of joint pain. And when the therapy was stopped there was some increase in the pain.”— WHI data showing systemic anti-inflammatory joint benefit of estrogen — and the regression on withdrawal.
Two distinct collagen supplement types serve different musculoskeletal targets
~1 h 10 min
UC-2 (undenatured type-2 collagen, 40 mg capsule) works via GI oral tolerance to suppress cartilage-degrading enzymes and may slow progression. Hydrolyzed type-2 collagen (500 mg powder) reduces symptoms of early knee arthritis but does not slow progression. Hydrolyzed type-1 collagen (the 'Fortibone' brand) has randomized trial evidence showing improved bone density in menopausal women, with gains comparable in size to those from strength + impact training programs.
Why this matters: Overturns the blanket dismissal of collagen supplements with mechanistically distinct options matched to specific clinical goals — and introduces a bone-density benefit most clinicians and patients have not heard.
Background
Dr. Wittstein initially dismissed collagen to patients but changed her recommendation after deep literature review. The key insight: type-2 collagen (for cartilage) and type-1 collagen (for bone) operate through completely different mechanisms and are often mislabeled together on generic supplement shelves.
The UC-2 mechanism: oral exposure to undenatured type-2 collagen (the same protein the immune system mistakenly attacks in some forms of joint inflammation) induces GI tolerance, dampening the immune cascade that breaks down cartilage. 'You expose your GI tract to this and it seems to reduce the levels of the enzymes which participate in breaking down cartilage and there are studies that show lower levels of cartilage breakdown products.' The Fortibone hydrolyzed type-1 collagen study: randomized trial, menopausal women with low bone density, found significant improvement in bone density, with a follow-up subset showing continued increase years later — gains in the same range as exercise programs. Wittstein's clinical recommendation: try both UC-2 and hydrolyzed type-2 collagen for joint symptoms, and hydrolyzed type-1 collagen for bone support.
A patient would ask me about collagen, I would say, 'That's dumb. Don't do that.' And then, you know, when I really went down a lot of rabbit holes and the more I read, I actually now recommend it to people.
Also said
“The undenatured version, the UC-2, kind of makes a little bit more sense to me because maybe — if something were going to slow progression — something that has less breakdown products would be better than something that maybe makes symptoms less but doesn't slow progression.”— Clinical reasoning for preferring UC-2 over hydrolyzed type-2 when the goal is disease modification vs. symptom relief.
DEXA screening at age 65 is too late — the MHT prevention window closes at ~10 years post-menopause
~2 h 25 min
Standard guidelines recommend the first DEXA scan at 65, but by then a woman who entered menopause at 52 is already 13 years out — past the window in which MHT initiation is considered safe and indicated for osteoporosis prevention. Dr. Wittstein runs a screening DEXA on all patients from age 40 onward with any risk factors.
Why this matters: The timing mismatch between current standard of care and the biological reality of the prevention window means millions of women are being offered the test at the exact moment the most effective preventive intervention is no longer appropriate.
Background
MHT has been FDA-approved for osteoporosis prevention for decades, but misinformation from the misread WHI study caused a generation of physicians to stop prescribing it — and the guidance update has not yet penetrated broadly into clinical practice.
Dr. Wittstein: 'If you get a DEXA scan when you're 65 and you already have osteoporosis and no one told you when you were 52 that menopausal hormone therapy can help prevent osteoporosis and prevents fractures in many people — now you're 65 and you're kind of out of the window of time where it's recommended to initiate menopausal hormone therapy, which is within 10 years of menopause.' Risk factors that should prompt earlier DEXA: menopause, Caucasian ethnicity, thin/underweight frame, personal history of amenorrhea or energy deficiency in youth, family history of osteoporosis. Under age 50 use Z-score (not T-score) for interpretation. The hard statistic motivating urgency: MHT reduces hip fracture risk 30%, vertebral fracture risk 40%, all-cause mortality ~30%.
I think the frustrating thing about the typical recommendation being to get a DEXA scan when you're 65 is that if you get a DEXA scan when you're 65 and you already have osteoporosis and no one told you when you were 52 that menopausal hormone therapy can help prevent osteoporosis... you're kind of out of the window of time where it's recommended to initiate menopausal hormone therapy, which is within 10 years of menopause.
Bone density is primarily built before age 30 — adolescent sports participation is the highest-leverage intervention
~1 h 55 min
Dr. Tammy Scarpella's 25-year longitudinal study of childhood gymnasts (tracked from age 7 with DEXA scans into adulthood) found 15–40% more bone density retained into adulthood versus non-athlete peers. After ~age 30, bone density declines; interventions can slow or partially reverse the loss but never exceed the age-30 ceiling.
Why this matters: Shifts the highest-leverage bone health conversation from postmenopausal supplementation to childhood and adolescent sports participation — a window most clinical bone health guidance ignores entirely.
Background
Most bone density research focuses on postmenopausal women, taking them from osteopenic or osteoporotic and trying to reverse loss. Scarpella's work is unusual in tracking bone accrual from childhood through adulthood.
After ~30, even with a good strength + impact exercise program, gains are a few percentage points over 6–8 months — enough to shift from osteoporotic (T-score below −2.5) to osteopenic (between −1.0 and −2.5), but nowhere near the peak that was set in youth. The message for adults: 'If you're not losing, you're winning, because the natural history would be to lose 1% of your bone mass per year. Or if you're a menopausal woman, 2% per year.' For parents: model exercise, get children into organized sports early, and understand that the female athlete triad / relative energy deficiency syndrome during adolescence can permanently deplete the bone bank before it has been fully built.
What she found was that these gymnasts ended up — depending on what part of the body — with 15 to 40% more bone density than their comparison group, maintained even into adulthood.
Low white-cell PRP combined with viscosupplementation is the most evidence-supported biologic for early knee arthritis
~1 h 25 min
Standard PRP has mixed evidence; the most effective variant is low-white-cell autologous conditioned plasma. There is basic science evidence that combining this with viscosupplementation (hyaluronic acid) potentiates the effect via lower inflammatory cytokine levels. These injections help symptoms but have not been proven to slow arthritis progression.
Why this matters: Gives a specific, technically precise recommendation rather than the blanket 'PRP is unproven' or 'PRP works' binaries most patients receive — and honestly states the limitation (symptom relief, not disease modification).
Background
Standard PRP preparations vary widely in white cell content; the white cells actually contribute to inflammation, so removing them produces a cleaner anti-inflammatory injectate.
Dr. Wittstein's spectrum approach for early knee arthritis (least to most invasive): (1) over-the-counter analgesics and topical NSAIDs (Voltaren); (2) corticosteroid injection — effective but use sparingly because repeated cortisone can soften cartilage over time; (3) low-white-cell PRP ± viscosupplementation; (4) surgical options if there is a focal cartilage defect rather than diffuse thinning. Important caveat: arthritis does progress regardless — the goal is to 'stay active as long as possible' and make strategic activity choices that don't accelerate symptoms.
What looks to be the most effective combination is something called low white cell autologous conditioned plasma, which is a type of PRP... there are basic science studies that show lower levels of inflammatory cytokines after that, lesser activation of macrophages and things that contribute to progression of arthritis.
Recommendations
Products, supplements, and tools mentioned in the episode
2 items
Fortibone hydrolyzed type-1 collagen (500 mg) for bone density
Supplement
The only collagen supplement brand Dr. Wittstein is aware of with published RCT data showing improvement in bone density in menopausal women with low bone mass, with gains comparable to exercise-based programs.
Dr. Wittstein: 'There's one brand that is studied — Fortibone — and they did a randomized study and found improvement in bone density in menopausal women with low bone density. And then they did a small subset of them several years later and showed an actual continued increase.' Type-1 collagen is the main structural collagen in bone. Hydrolyzed form allows absorption. Gains in the same range as strength training + impact programs.
There's one brand that is studied, which is called Fortibone. They took hydrolyzed type-1 collagen — type-1 collagen is the main type of collagen in bone — and did a randomized study and found improvement in bone density in menopausal women with low bone density.
UC-2 undenatured type-2 collagen (40 mg) for cartilage protection
Supplement
A 40 mg capsule of undenatured type-2 collagen taken daily works via GI oral tolerance to reduce immune enzymes that degrade cartilage. May slow progression where hydrolyzed type-2 only relieves symptoms.
Dr. Wittstein explains the mechanism: 'You expose your GI tract to this and it seems to reduce the levels of the enzymes which participate in breaking down cartilage — and there are studies that show lower levels of cartilage breakdown products.' Her practical recommendation: take both UC-2 and hydrolyzed type-2 together for joint symptoms. Contrast with type-1 collagen (for bone) and type-3 (for skin/connective tissue) — commonly blended on supplement shelves in ways that obscure which type is present.
vs alternatives
Hydrolyzed type-2 collagen (500 mg) reduces symptom severity in early knee arthritis but has not been shown to slow progression. UC-2 (40 mg) may slow progression by reducing cartilage breakdown enzymes. Wittstein recommends trying both together.
The undenatured version, the UC-2, works through like an immunologic response or through a system called GI tolerance. You expose your GI tract to this and it seems to reduce the levels of the enzymes which participate in breaking down cartilage.
The Complete Bone and Joint Health Plan by Jocelyn Wittstein MD (with Sydney Norski RD)
Book Sponsored · disclosed
Comprehensive guide for non-medical readers covering what arthritis is, what osteoporosis is, what to do for joint health, and how to prevent and treat both — written so patients arrive at their doctor's appointments well-armed with information.
DisclosureGuest's own book, released May 6, 2025. Dr. Wittstein is co-author.
Dr. Wittstein describes it as the book she always wanted to write because 'I cannot say enough of what I want to say in a visit to patients.' Co-authored with dietician Sydney Norski RD. Written for patients who need to understand mechanisms, not just instructions, so they can ask the right questions.
This book is just something I always wanted to do. I tried to put everything all in one place that all of my patients ask me all the time — what is arthritis, what is osteoporosis, what you can do to help your joints, what you can do to prevent or treat osteoporosis and arthritis if you have it.
Omega-3 fatty acids (EPA + DHA preferred over ALA) support muscle, brain, and heart health and help balance omega-6 fatty acids. Lyon adds opened capsules to her children's milk for brain development support.
DisclosureEpisode sponsor and Lyon's personally-used product. Code drlion at pori.com/drion for 20% off.
Dr. Lyon describes third-party testing and certification by the Clean Label Project and IFOS as her trust criteria: 'Every batch is tested against more than 200 contaminants with all their results published online.' In the joint context, omega-3 modulates the prostaglandin-resolving pathway that reduces tendinopathy, offering a lower-side-effect alternative to chronic NSAID use.
There continues to be good data on the use of omega-3 fatty acids in muscle, brain, heart health along with balancing omega-6 fatty acids. This is a source of omega-3 that I trust and highly recommend.
Lines worth pulling out — contrarian, specific, or perfectly phrased
6 items
Estrogen is a major anti-inflammatory hormone and there are estrogen receptors all over the human body — skeletal muscle, bones, synovium of joints, your tendons and ligaments. When we get estrogen decline we get higher levels of inflammation.
The single sentence that reframes frozen shoulder, arthritis, osteoporosis, and tendinitis as expressions of one hormonal event rather than separate age-related diseases.
If you look at studies that compare runners to non-runners, runners are less likely to have arthritis than age and sex matched groups.
Directly contradicts one of the most persistent and mobility-limiting myths in orthopedic medicine. Clean, counterintuitive, and well-supported.
It was labeled as idiopathic forever. And you know what idiopathic means? It means we just don't know what causes it. But how can it be idiopathic if this happens mostly in women and not in men?
The framing that turns frozen shoulder from a 'mystery' into a predictable, estrogen-mediated, potentially preventable condition — and an indictment of how female-predominant conditions get labeled.
Menopausal hormone therapy could be considered a life-saving thing. It reduces your risk of a hip fracture by 30%, reduces your risk of a vertebral fracture by about 40%, and reduces your all-cause mortality by about 30%.
The quantified benefit statement that every perimenopausal woman should hear before the 10-year initiation window closes. Most patients don't know MHT has mortality data.
If you're not losing, you're winning — because the natural history would be to lose 1% of your bone mass per year. Or if you're a menopausal woman, 2% per year.
Reframes the achievable goal for adults: not 'build more bone than at age 30' but 'stop the default decline' — realistic and motivating.
A patient would ask me about collagen, I would say, 'That's dumb. Don't do that.' And then I went down a lot of rabbit holes and the more I read, I actually now recommend it to people.
A rare public admission of a changed clinical opinion backed by the mechanistic detail that explains the reversal — a model of how experts should update.
Sign in to share feedback
Tell us if this brief hit the mark or missed it — feedback feeds back into the next iteration of the prompt.
Reading is free for everyone. A free account adds the personal layer: save protocols, follow experts, and see how the other experts weigh in on this same topic.
Educational summary of the cited expert source — not medical advice. Open the source recording linked above and consult a qualified physician before acting on any protocol.
